Therapies for Long COVID in non-hospitalised individuals

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from TLC Study)

The TLC Study or Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient-reported outcomes and immunology to targeted therapies.[1][2]

Funding

£2.2m over two years. Funded by the UK National Institute for Health Research (NIHR) and UK Research and Innovation.[3]

Results

None published yet.

Criticism

Investigators

  • Shamil Haroon, University of Birmingham - Principal Investigator
  • Melanie Calvert, University of Birmingham - Co-Principal Investigator[4]

Other researchers include Dr Krish Nirantharakumar, Dr Joht Singh Chandan, Dr Olalekan Lee Aiyegbusi, Professor Janet Lord, Professor David Wraith, Professor Alastair Denniston, Dr Sarah Hughes, Dr Louise Jackson, Dr Grace Turner, Dr Samantha Cruz Rivera, Dr Anuradhaa Subramanian, Professor Georgios Gkoutos, Professor Elizabeth Sapey, Professor Tom Marshall, Dr Christel McMullan, Professor Steven Marwaha, and COVID-19 survivor Gary Price who will also act as a co-investigator.

It also includes Dr Puja Myles and Dr Tim Williams, of the Medicines and Healthcare products Regulatory Agency (MRHA), and Dr Elin Haf Davies, of Aparito Limited.[3]

Project partners

News and articles

See also

Learn more

References

  1. ↑ "Research into the longer term effects of COVID-19 in non-hospitalised individuals- Funding Panel Meeting Minutes". nihr.ac.uk. Retrieved March 1, 2021.
  2. ↑ "£18.5 million to tackle 'Long-COVID' in the community – UKRI". ukri.org. Retrieved March 1, 2021.
  3. ↑ 3.0 3.1 "£2.2m research project aims to improve treatment and understanding of Long COVID". Birmingham Health Partners. February 18, 2021.
  4. ↑ "Professor Mel Calvert". srmrc.nihr.ac.uk. July 30, 2019. Retrieved March 1, 2021.
Retrieved from "https://me-pedia.org/w/index.php?title=Therapies_for_Long_COVID_in_non-hospitalised_individuals&oldid=240334"